CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 146 enrolled
Drug / intervention
ABT-493/ABT-530drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02642432
NCT02642432Phase 3Completed
CompareCT.gov

A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

AbbVie·interventional·Posted Dec 30, 2015·Updated Jul 13, 2021

In Brief

A Phase 3 clinical trial evaluating ABT-493/ABT-530 for Hepatitis C Virus Infection and 2 related conditions. Completed, enrolled 146 participants.

Detailed Summary

The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 30, 2015
Enrollment StartDec 7, 2015
Primary CompletionOct 27, 2016
Study CompletionFeb 10, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.5 years ago

Interventions

ABT-493/ABT-530drug

Tablet; ABT-493 coformulated with ABT-530